Jazz Pharmaceuticals plc
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ), headquartered in Dublin, Ireland and founded in 2003, develops and commercializes innovative biopharmaceutical products for serious diseases with significant unmet needs, primarily in neuroscience and oncology; its core portfolio includes Xywav and Xyrem (sodium oxybate formulations) for cataplexy and excessive daytime sleepiness in narcolepsy, Epidiolex (cannabidiol oral solution) for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, Defitelio (defibrotide) for severe hepatic veno-occlusive disease post-hematopoietic stem-cell transplantation, Rylaze (asparaginase erwinia chrysanthemi recombinant) for acute lymphoblastic leukemia, Vyxeos (daunorubicin and cytarabine liposome injection) for therapy-related acute myeloid leukemia and newly diagnosed acute myeloid leukemia, Zepzelca (lurbinectedin) for metastatic small cell lung cancer, Modeyso (vosoritide) for achondroplasia in pediatric patients, and Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer; products are marketed in nearly 75 countries across North America, Europe, and select international markets including Australia, Israel, Japan, Canada, and parts of the Middle East and Latin America. Recent developments include FDA approval of Ziihera (zanidatamab-hrii) in November 2024 for biliary tract cancer with ongoing pursuits in HER2-positive breast cancer, a March 2025 definitive agreement to acquire Chimerix for approximately $935 million to bolster its pipeline, an August 2025 exclusive licensing agreement with Saniona for SAN2355 targeting epilepsy and neurological conditions where Jazz leads global development and commercialization, a February 2024 deal with Redx Pharma acquiring global rights to a KRAS inhibitor program for up to $880 million, and a October 2025 research collaboration with Iambic Therapeutics on AI-driven drug discovery. The company maintains manufacturing facilities in Ireland, England and Italy, with significant operations in Palo Alto, Philadelphia, Oxford and Cambridge.
Company News
Jazz Pharmaceuticals PLC $JAZZ Position Lifted by CWA Asset Management Group LLC
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?
Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT)
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
Engineers Gate Manager LP Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?